ReviewFrontiers in pharmacology2021
Transition From Full Mu Opioid Agonists to Buprenorphine in Opioid Dependent Patients-A Critical Review.
Review in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- Evidence-based consensus guidelines for the pharmacological management of substance dependence: Recommendations from the British Association for Psychopharmacology.Journal of psychopharmacology (Oxford, England) · 2026Guideline
- Antenatal Opioid Exposure and Cerebral Cortical Maturation in Newborns.JAMA network open · 2026Article
- Buvidal/Brixadi - a long-acting injectable buprenorphine formulation for the treatment of opioid dependence.Pain management · 2025Review
- Impact of general anesthesia on feline aqueous tear production and the feline corneal epithelium.Journal of feline medicine and surgery · 2025Article
- Long-Acting injectable buprenorphine PLGA microparticle formulation.International journal of pharmaceutics · 2025Article
- Treating Opioid Use Disorder and Opioid Withdrawal in the Context of Fentanyl.Annual review of clinical psychology · 2025Review
- Buprenorphine Pharmacodynamics: A Bridge to Understanding Buprenorphine Clinical Benefits.Drugs · 2025Review
- Gestational Opioid Exposure: From Morphine to MOUD - How Opioids Impact Offspring Development and Maternal Care.Current topics in behavioral neurosciences · 2025Review
- Ketamine-assisted buprenorphine initiation: a pilot case series.Addiction science & clinical practice · 2024Article
- Effect of TRV130 and methadone on fentanyl-vs.-food choice and somatic withdrawal signs in opioid-dependent and post-opioid-dependent rats.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2022Article
- Diels-Alder Adducts of Morphinan-6,8-Dienes and Their Transformations.Molecules (Basel, Switzerland) · 2022Review
- Article
- Opioid Addiction Medicine in Nigeria: Bridging Clinical Gaps in a Silent Epidemic-A Narrative Review.Nigerian medical journal : journal of the Nigeria Medical AssociationReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Methadone, a full opioid agonist at the mu-, kappa-, and delta-receptor, and buprenorphine, a partial agonist at the mu receptor, are first-line medications in opioid maintenance treatment. Transition from methadone to buprenorphine may precipitate withdrawal, and no accepted algorithm for this procedure has been developed. Current treatment strategies recommend transfer from methadone to buprenorphine predominantly in patients at low doses of methadone (30-40 mg/day). There are some reports indicating that transition from higher doses of methadone may be possible. A number of dosing strategies have been proposed to soften withdrawal symptoms and facilitate transfer including use of other opioids or medications and especially microdosing techniques for buprenorphine. The case series and studies available thus far are reviewed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.